secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K/A
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001731122-24-001573
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax CEO & CFO resign amid disagreements; Nasdaq warns of bid price deficiency
--------------------------------------------------------------------------------

- CEO Gerald Bruce and CFO Vinay Shah resigned Oct 5, citing disagreements with Board's execution of policies.
- Board appointed director Jatinder Dhaliwal as new CEO effective Oct 6; Katharyn Field replaces him on audit committee.
- Nasdaq notified company Oct 4 that bid price below $1.00 for 30 consecutive days; 180-day cure period until Apr 2, 2025.
- Company disagrees with allegations in Bruce's resignation letter, filed as exhibit.
- If not compliant by Apr 2, 2025, may get second 180-day period; delisting risk if not cured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001573/0001731122-24-001573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001573/e6017_8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001731122-24-001573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer